Related Experiment Videos
De novo malignancy after liver transplant
Ahmad Khalid Sanaei1, Mohsen Aliakbarian, Kourosh Kazemi
1From the Shiraz Transplant Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Summary
Liver transplant recipients have a high risk of de novo malignancies. Posttransplant lymphoproliferative disorder was the most common, particularly in children, leading to significant morbidity and mortality.
Area of Science:
- Transplantation medicine
- Oncology
- Immunology
Background:
- Liver transplant recipients face an increased risk of de novo malignancies.
- Understanding the incidence and types of these cancers is crucial for patient management.
Purpose of the Study:
- To evaluate the incidence and histologic types of de novo malignancies.
- To analyze post-liver transplant cancer development in a dedicated transplant center.
Main Methods:
- Retrospective analysis of 1700 patients undergoing orthotopic liver transplant.
- Data collected from January 1992 to October 2012.
Main Results:
- 38 patients (2.2%) developed de novo malignancy.
- Posttransplant lymphoproliferative disorder (PTLD) was most common (63%), primarily affecting children (<10 years), with a 21% mortality rate.
- Other malignancies included gastrointestinal adenocarcinoma, Kaposi sarcoma, and thyroid cancer.
Conclusions:
- PTLD is the most frequent malignancy post-liver transplant, especially in pediatric recipients, contributing significantly to morbidity and mortality.
- Preventive and early diagnostic strategies are essential to reduce de novo malignancy-related complications.
- Further research into risk factors and management of PTLD in liver transplant patients is warranted.